Saturday 17 October 2026
Export OWLT’s income statement to Excel — free account
Owlet, Inc.
OWLT Healthcare Medical Devices
In the quarter to June 2026, revenue grew 29.9%, EPS grew 97.9%, free cash flow grew 55.7% and total debt fell 16.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
4.14
0.30
−6.76%
Follow OWLT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.38 | 2.77 | 1.32 | 1.42 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(63.22) | (648.10) | (27.91) | (1,779.03) | |
P/B ratio |
0.00 | 15.38 | 6.71 | 7.07 | |
Price to Tangible BV |
0.00 | 16.60 | 7.32 | 7.75 | |
EV/Sales |
1.39 | 2.51 | 1.11 | 1.27 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(18.83) | (24.55) | (11.97) | (18.82) | |
EV/FCF |
(17.34) | (22.58) | (10.63) | (14.82) | |
Quick Ratio |
0.84 | 1.45 | 1.26 | 1.29 | |
Current Ratio |
1.14 | 1.85 | 1.71 | 1.64 | |
Net Debt/EBITDA |
0.47 | 6.20 | 4.51 | (8.52) | |
Debt/Assets |
33.32% | 15.22% | 21.63% | 18.24% | |
Debt/Equity |
(0.58) | 0.42 | 0.55 | 0.46 | |
Asset Turnover |
1.52 | 1.56 | 1.55 | 1.46 | |
Operating CF/Net income |
(0.81) | 0.05 | 1.22 | 0.06 | |
Capex/Depreciation |
(0.37) | (0.80) | (0.75) | (1.72) | |
Interest Coverage |
1.41 | (8.71) | (8.04) | 2.46 | |
Research and Development Expense of Revenue |
11.83% | 13.78% | 17.62% | 13.47% | |
Selling, General and Administrative Expense of Revenue |
35.01% | 53.07% | 61.34% | 45.83% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
4.32% | 18.20% | 15.54% | 9.55% | |
Graham Net Nets |
(0.34) | 0.09 | 0.21 | 0.19 | |
Graham Number |
14.30 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(32.11%) | (15.32%) | (53.31%) | (7.32%) | |
Free Cash Flow Yield |
(5.80%) | (4.01%) | (7.92%) | (6.03%) | |
Revenue per Share |
1.97 | 1.47 | 0.82 | 1.19 | |
Operating CF per Share |
(0.13) | (0.02) | (0.18) | 0.00 | |
Capex per Share |
(0.02) | (0.03) | (0.02) | (0.03) | |
Free Cash Flow per Share |
(0.15) | (0.05) | (0.20) | (0.04) | |
Cash per Share |
1.49 | 2.27 | 1.50 | 1.28 | |
Shareholders Equity per Share |
(2.65) | 1.72 | 1.23 | 1.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.65) | 1.72 | 1.23 | 1.29 | |
Free Cash Flow |
(2.42) | (0.94) | (5.46) | (1.03) | |
Working Capital |
8.70 | 37.67 | 34.31 | 34.48 | |
Capital Expenditures |
(0.25) | (0.49) | (0.41) | (0.94) | |
Net Current Asset Value |
(46.22) | 27.32 | 29.55 | 31.58 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.02 | 0.02 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
22.87 | 17.53 | 18.19 | 28.75 | |
Average Payables |
14.59 | 11.62 | 12.24 | 12.52 | |
Average Inventory |
12.56 | 12.91 | 15.00 | 13.52 | |
Average Assets |
65.50 | 67.57 | 69.08 | 78.56 | |
Average Common Equity |
(37.80) | (5.35) | (2.40) | (18.01) |
Columns are period end dates